Hepatotoxicidad por antifímicos, en pacientes con tuberculosis pulmonar y su relación con el consumo de sustancias psicotrópicas, Hospital General Guasmo Sur, 2018.

Abstract

Introduction: Pulmonary tuberculosis is one of the biggest health problems, it’s estimated that around 10 million people suffered from this disease worldwide in 2018. The established treatment if it’s properly carried out yields the expected results; however the inconvenient of this Antifimic scheme is that it tends to develop liver disorders, which can be increased by the psychotropic substances use. Objective: Describe hepatotoxicity by Antifimic treatment in patients with pulmonary tuberculosis and its relationship with the psychotropic substances use. Hospital General Guasmo Sur, during 2018. Methodology: This is an analytical, retrospective and cross-sectional study, where the electronic medical records of patients with pulmonary tuberculosis from the Hospital General Guasmo Sur were reviewed during 2018. Results: Of the 132 patients studied, 83% corresponded to psychotropic substances consumers while the remaining 17% did not; alkaline phosphatase was the most elevated enzyme as evidence of hepatotoxicity. Of this population mentioned above, 85.61% belongs to the male sex and 14.39% to the female sex. Talking about the age, there were more cases in the group of 20 to 29 years with 35.61%. Conclusion: A large part of the patients with pulmonary tuberculosis who developed liver toxicity during the administration of Antifmic treatment, mainly corresponded to the group with a history of consumption of psychotropic substances.